<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MUPIROCIN</span><br/>(mu-pi-ro'sin)<br/><span class="topboxtradename">Bactroban, </span><span class="topboxtradename">Bactroban Nasal<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">pseudomonic acid antibiotic</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2% ointment; cream</p>
<h1><a name="action">Actions</a></h1>
<p>Topical antibacterial produced by fermentation of <i>Pseudomonas fluorescens</i>.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits bacterial protein synthesis by binding with the bacterial transfer-RNA. Susceptible bacteria are <i>Staphylococcus aureus</i> [including methicillin-resistant (MRSA) and beta-lactamase-producing strains], <i>Staphylococcus epidermidis, Staphylococcus saprophyticus,</i> and <i>Streptococcus pyogenes.</i>
</p>
<h1><a name="uses">Uses</a></h1>
<p>Impetigo due to <i>Staphylococcus aureus, beta-hemolytic Streptococci</i>, and <i>Streptococcus pyogenes;</i> nasal carriage of <i>S. aureus.</i>
</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Superficial skin infections.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any of its components and for ophthalmic use.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Burn patients; pregnancy (category B) or lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Impetigo</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">Topical</span> Apply to affected area t.i.d., if no response in 35 d, reevaluate (usually continue for 12 wk)<br/><br/><span class="indicationtitle">Elimination of Staphylococcal Nasal Carriage</span><br/><span class="rdage">Child:</span> <span class="rdroute">Intranasal</span> Apply intranasally b.i.d. to q.i.d. for 514 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply thin layer of medication to affected area.</li>
<li>Cover area being treated with a gauze dressing if desired.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Burning, stinging, pain, pruritus, rash, erythema, dry skin, tenderness, swelling. <span class="typehead">Special Senses:</span> Intranasal, local stinging, soreness, dry skin, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Incompatible with <b>salicylic acid 2%</b>; do not mix in <span class="classification">hydrophilic vehicles</span> (e.g., <b>Aquaphor</b>) or <span class="classification">coal tar solutions</span>; <b>chloramphenicol</b> may interfere with bactericidal action of mupirocin. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Not systemically absorbed. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Watch for signs and symptoms of superinfection (see Appendix F). Prolonged or repeated therapy may result in superinfection
            by nonsusceptible organisms.
         </li>
<li>Reevaluate drug use if patient does not show clinical response within 35 d.</li>
<li>Discontinue the drug and notify physician if signs of contact dermatitis develop or if exudate production increases.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue drug and contact physician if a sensitivity reaction or chemical irritation occurs (e.g., increased redness, itching,
            burning).
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>